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The U1 small nuclear RNA (snRNA)—in the form of the U1
spliceosomal Sm small nuclear ribonucleoprotein particle (snRNP)
that contains seven Sm and three U1-specific RNP proteins—has a
crucial function in the recognition and removal of pre-messenger
RNA introns. Here, we show that a fraction of human U1 snRNA
specifically associates with the nuclear RNA-binding protein
TBP-associated factor 15 (TAF15). We show that none of the
known protein components of the spliceosomal U1-Sm snRNP
i n t e r a c t sw i t ht h en e w l yi d e n t i f i e dU 1 - T A F 1 5s n R N P .I na d d i t i o n ,
the U1-TAF15 snRNP tightly associates with chromatin in an
RNA-dependent manner and accumulates in nucleolar caps upon
transcriptional inhibition. The Sm-binding motif of U1 snRNA is
essential for the biogenesis of both U1-Sm and U1-TAF15 snRNPs,
suggesting that the U1-TAF15 particle is produced by remodelling
of the U1-Sm snRNP. A demonstration that human U1 snRNA
forms at least two structurally distinct snRNPs supports the idea
that the U1 snRNA has many nuclear functions.
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INTRODUCTION
The U1 spliceosomal Sm small nuclear ribonucleoprotein particle
(snRNP), which is composed of the 164-nucleotide-long U1 small
nuclear RNA (snRNA), seven Sm proteins (B, D1, D2, D3, E, F and
G) and three U1-specific (U1-70K, U1-A and U1-C) snRNP
proteins, together with the U2, U4, U5 and U6 snRNPs, and many
dozens of protein factors, constitutes the spliceosome that is
responsible for the removal of pre-messenger RNA (pre-mRNA)
introns (Will & Lu ¨hrmann, 2006). At the early stage of spliceosome
assembly, the U1 snRNP associates with the 50 splice site through
RNA–RNA and protein–RNA interactions, committing the nascent
pre-mRNA to the splicing pathway. The U1 snRNP/snRNA has
also been implicated in the enhancement of transcription
initiation by RNA polymerase II (Pol II; Kwek et al, 2002;
Damgaard et al, 2008), stabilization of nascent pre-mRNAs
(Hicks et al, 2006) and control of viral pre-mRNA polyadenylation
(Gunderson et al, 1998).
Biogenesis of Sm snRNPs is a complex process (Kiss, 2004).
After synthesis by Pol II, the precursor snRNAs (pre-snRNAs) are
exported to the cytoplasm, where their assembly with the seven
Sm core proteins is promoted by the survival of motor neurons
(SMNs) complex. Binding of Sm proteins is essential for both
hypermethylation of the primary monomethyl-G cap to trimethyl-G
(TMG) and removal of the 30 tail sequences of pre-snRNAs.
Finally, the nascent Sm snRNPs are imported to the nuclear Cajal
bodies where their snRNA components undergo site-specific
nucleotide modifications (Jady et al, 2003).
During the initiation of Pol II transcription, the general Pol II
transcription factor IID (TFIID) is the first general transcription
factor that recognizes promoter sequences and initiates assembly
of the preinitiation complex. TFIID is composed of the TATA-
binding protein (TBP) and a series of TBP-associated factors
(TAFs). TAF15, formerly known as TAFII68, has been identified as
a TAF that interacts with a distinct population of TFIID (Bertolotti
et al, 1996). In addition to a transcriptional activation domain,
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494TAF15 also contains an RNA recognition motif (RRM) and many
Arg-Gly-Gly repeat motifs, suggesting that it functions as an RNA-
binding protein. TAF15 and the structurally related EWS (Ewing
sarcoma) and TLS (translocated in liposarcoma) constitute the TET
family of proteins. In human sarcomas, translocation of TET genes
frequently results in chimaeric oncoproteins (Law et al, 2006). The
TET proteins have been suggested to have a function in regulating
transcription (Bertolotti et al, 1996, 1999; Jobert et al, 2009) or
in the splicing of pre-mRNA (Law et al, 2006, and references
therein), but their precise function remains elusive.
RESULTS AND DISCUSSION
TAF15 forms a new snRNP with U1 snRNA
To detect cellular RNA partners for TAF15, it was immunoprecip-
itated from a HeLa nuclear extract with two different TAF15
antibodies, and the co-precipitated RNAs were terminally labelled
and size-fractionated on a denaturing gel (Fig 1A). Both RNA
samples recovered by the TAF15 antibodies were highly enriched
by an approximately 165-nucleotide-long RNA that was hardly
detectable in control immunoprecipitations. The efficient immuno-
precipitation of TAF15 was confirmed by Western blot. When
labelled nuclear RNA was run in parallel, it became apparent
that the most abundant TAF15-associated RNA co-migrated with
U1 snRNA.
To determine unequivocally the identity of the newly
detected TAF15-associated RNA, RNase A/T1 protection analysis
was carried out by using an RNA probe complementary to the
predominant U1A sequence variant of the human U1 snRNA
(Fig 1B). RNA co-immunoprecipitated with TAF15 protected
the U1A probe, but failed to protect RNA probes specific
for the U2 and U4 snRNAs. None of the RNA probes was
efficiently protected by mock-immunoprecipitated RNAs.
An RNA-immunoprecipitation assay confirmed the in vivo
association of TAF15 with U1 (supplementary Fig 1 online).
Thus, we conclude that human U1 snRNA specifically associates
with TAF15.
Many RNA-binding proteins, including U1-70K and TAF15,
share an RRM that contains the conserved eight- and six-residue
RNP1 and RNP2 motifs. The first two amino acids (Arg143 and
Gly144) of the RNP1 motif of U1-70K have been shown to be
fundamental for binding to U1 snRNA (Surowy, 1989). To test
whether the RRM of TAF15 is important for in vivo binding to
U1, the first and second residues (Lys280 and Gly281)
in the RNP1 motif of TAF15 were replaced by proline (P) and
serine (S), respectively. The resulting TAF15 K280P and G281S
mutants, as well as the wild-type TAF15, were transiently
expressed as Flag-tagged proteins in HeLa cells. Following
anti-Flag immunoprecipitations, the recovery of U1 snRNA was
monitored by reverse transcription–quantitative PCR (RT–qPCR;
Fig 1C). As compared with the wild-type Flag–TAF15, the mutant
Flag–TAF15 K280P and Flag–TAF15 G281S proteins showed
about 54% and 64% reduced U1-binding capacities, respectively,
indicating that the RNP1 motif contributes to the U1-binding
capacity of TAF15.
To determine whether TAF15 binds to a fraction of the U1-Sm
snRNP or whether it is a component of a new, not yet identified
minor U1 snRNP, co-immunoprecipitation experiments were
performed (Fig 1D). Although immunoprecipitation of TAF15
efficiently recovered U1 snRNA, it failed to pull down detectable
267
U3
Anti-control mAb
Anti-TAF15 (7TA)
Anti-TAF15 (8TA)
Total RNA
Nuclear RNA
Anti-control
Anti-U1-70K
Anti-TAF15
U2
U2
U1
U1
U4
U4
5.8S
5S
U5
234
213
213 192
192 184
184
192
184
141 141
141
123 123
104
89
M12 3
12 3
IP
4
4
IN
TAF15
TAF15
U1-70K
U1-A
U1-C
Sm D1/D3
1234
tRNA
56
M12 3456
–Ab
Anti-control mAb
Anti-TAF15 (7TA)
Anti-TAF15 (8TA)
Total RNA
Control
–Ab
A
D
B
Flag
Flag–TAF15
Flag–TAF15 K280P
Flag–TAF15 G281S
12
0.2
0.1
0
U1 snRNA normalized
A
r
b
i
t
r
a
r
y
 
u
n
i
t
s 34
1234
TAF15
C
Fig 1 |TAF15 forms a new snRNP with U1 snRNA. (A) Immuno-
precipitations (IP) were performed from a HeLa nuclear extract with two
TAF15 antibodies (lanes 3 and 4), a control antibody (lane 2) or with
protein G-Sepharose alone (lane 1). RNAs co-precipitated with TAF15,
HeLa total and nuclear RNAs were terminally labelled and separated on a
sequencing gel (upper panel). TAF15 immunoprecipitation was analysed
by Western blot (lower panel). (B) RNAs precipitated by TAF15
antibodies, protein G-Sepharose alone ( Ab) or a control antibody
were analysed by RNase A/T1 mapping with RNA probes specific for
U1, U2 or U4 snRNAs. The protected RNAs were fractionated on a
sequencing gel. Lane 1, control mapping with Escherichia coli tRNA.
(C) Transiently expressed Flag, Flag–TAF15, Flag–TAF15 K280P or
Flag–TAF15 G281S proteins were immunoprecipitated by Flag antibodies.
Co-immunoprecipitation of U1 snRNA was measured by RT–qPCR and
normalized with the amount of U1 co-precipitated with Flag–TAF15.
(D) Immunoprecipitations from a HeLa nuclear extract (IN) were
performed with antibodies as indicated. The co-immunoprecipitated
proteins were analysed by Western blot. Ab, antibody; M, size marker;
mAb, monoclonal antibody; RT–qPCR, reverse transcription–quantitative
PCR; snRNA, small nuclear RNA; snRNP, small nuclear ribonucleoprotein
particle; TAF, TBP-associated factor 15; tRNA, transfer RNA.
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495amounts of the U1-70K, U1-A, U1-C and D1/D3 Sm proteins
that are integral components of the U1-Sm snRNP. By contrast,
all of the tested U1 snRNP proteins were efficiently recovered
by immunoprecipitation performed with a U1-70K antibody.
A trace amount of TAF15 detected in the pellet of the anti-
U1-70K immunoprecipitation probably derived from a weak
cross-reaction of the U1-70K antibody with TAF15. This assump-
tion was confirmed by the fact that U1-70K failed to co-precipitate
with a transiently expressed Flag-tagged TAF15 when it
was immunoprecipitated with a Flag antibody (supplementary
Fig 2 online).
TAF15 associates with the main isoform of U1 snRNA
Although human cells express minor sequence variants of the U1
snRNA (Kyriakopoulou et al, 2006), direct RNA sequencing
of 30-end labelled TAF15-associated U1 snRNA has revealed a
nucleotide sequence identical to the Gly41–Gly164 30-terminal
portion of the most abundant U1A sequence variant of U1 snRNA
(data not shown). Consistent with this, the TAF15-bound U1
snRNA efficiently protected the U1A-specific antisense RNA
probe (Fig 1B), showing that TAF15 predominantly associates
with the abundant U1A snRNA.
The mature U1-Sm snRNA contains an internal 20-O-ribose-
methylated adenosine (A70), two pseudouridines (C5 and C6) and
a5 0-terminal TMG cap. To test whether these post-transcriptional
modifications are also present in the TAF15-associated U1 snRNA,
the U1-TAF15 snRNP and a positive control, the U1-Sm snRNP,
were immunoprecipitated from a HeLa nuclear extract with
TAF15- and Sm-specific antibodies (Fig 2A). Consistent with the
conclusion that TAF15 and Sm proteins form two distinct snRNPs
with U1, the pellets of the Sm and TAF15 immunoprecipitation
reactions were devoid of TAF15 and Sm proteins, respectively. The
U1 snRNA co-precipitated with TAF15 was further analysed by
immunoprecipitation with TMG and H-20 (specific for both TMG
and monomethyl-G) antibodies (Fig 2B). RNase A/T1 mapping
revealed that both antibodies immunoprecipitated U1 snRNA,
showing that the TAF15-bound U1 snRNA carries a TMG cap.
The 20-O-methylation status of A70 in the TAF15-associated U1
snRNA was determined by primer extension analysis in the
presence of low dNTP concentration, which is known to stop
reverse transcriptase before the methylated nucleotide (Jady et al,
2003; Fig 2C). When TAF15- or Sm-associated U1 snRNAs were
analysed with a U1-specific primer at low dNTP concentration, a
strong stop signal was observed before A70 in both cases, showing
that the A70 residue is 20-O-methylated in both U1 samples.
Pseudouridylation of the U5 and U6 residues was determined
by the CMC primer extension method (Fig 2D). CMC reacts with
pseudouridines and arrests reverse transcriptase one nucleotide
before them (Jady et al, 2003). Primer extension analysis of
CMC-treated TAF15- and Sm-associated U1 snRNAs resulted in
stops one nucleotide before the U5 and U6 residues, showing that
these uridines are converted into pseudouridine. In summary, we
conclude that the U1 snRNA components of the U1-TAF15 and
U1-Sm snRNPs have no distinctive structural characteristics.
Biogenesis of U1-TAF15 snRNP requires the Sm motif of U1
A demonstration that the U1-TAF15 snRNP lacks Sm proteins,
but its snRNA component is correctly processed suggests
that the TAF15-associated fraction of U1 snRNA follows an
‘Sm-independent’ processing pathway. To test this, a series of
mutant U1 snRNAs, U1sm1 to U1sm5, carrying altered Sm-binding
motifs were transiently expressed in HeLa cells (Fig 3A). RNase A/T1
mappings revealed a weak accumulation for each mutant U1 RNA.
Besides mature-sized U1 RNAs, we detected several 30-extended
unprocessed or partly processed pre-U1 snRNAs, which were also
present in non-transfected cells.
To determine the subcellular localization of the weakly
expressed mutant U1 RNAs, the U1sm3 RNA and as a control,
an Sm mutant U2 snRNA (U2sm), were expressed in HeLa cells
(Fig 3B). In contrast to U1sm3, only one 30-extended precursor
form of the U2sm RNA accumulated. Mapping of cytoplasmic and
nuclear RNAs revealed that the U2sm RNA and all variants of the
U1sm3 RNA accumulated exclusively in the cytoplasm, indicating
that they represent dead-end products of snRNA biogenesis.
Consistently, neither Sm nor TAF15 antibodies pulled down
U1sm3 RNAs (Fig 3C). A demonstration that the Sm motif is
essential not only for the biogenesis of the U1-Sm snRNP but also
for the accumulation of the U1-TAF15 snRNP, strongly supports
the idea that U1-TAF15 is produced by remodelling of the U1-Sm
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Fig 2 |Characterization of U1 snRNA associated with TAF15. (A) HeLa
U1-TAF15 and U1-Sm snRNPs were immunoprecipitated from a nuclear
extract (IN) with antibodies specific for TAF15 and SmD proteins and
analysed by Western blot. (B) U1 snRNA co-purified with TAF15
was immunoprecipitated with TMG or H-20 antibodies. Mock
immunoprecipitation (Ctrl) was performed with beads alone.
RNAs recovered from the supernatant (S) and pellet (P) of each
immunoprecipitation were analysed by RNase A/T1 mapping. (C)U 1
RNAs associated with Sm or TAF15 were analysed by primer extension
in the presence of 1 or 0.04mM dNTPs. (D) Sm- or TAF15-associated U1
RNA, either treated (þ) or non-treated ( ) with CMC, was analysed by
primer extension. A, G, C and T: dideoxy sequencing ladders. Am70,
methylated adenosine 70; M, size marker; SmD, one of the members of
the nine Sm core proteins that bind to snRNAs (U1, U2, U4 and U5);
snRNA, small nuclear RNA; snRNP, small nuclear ribonucleoprotein
particle; TAF15, TBP-associated factor 15; TMG, trimethyl-G.
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496snRNP after reimportation from the cytoplasm. The cytoplasmic
assembly of Sm snRNPs is promoted by the SMN complex that can
also facilitate the disassembly of Sm snRNPs (Chari et al, 2008).
Thus, SMN might participate in the biogenesis of U1-TAF15
snRNP by promoting the disassembly of U1-Sm snRNP. The
SMN-dependent biogenesis of U1-TAF15 might take place in the
Cajal bodies, as spliceosomal snRNPs repeatedly cycle through
Cajal bodies (Stanek et al, 2008) and SMN accumulates in these
nucleoplasmic organelles (Battle et al, 2006).
The U1-TAF15 snRNP associates with chromatin
Cell extracts prepared in the presence of 0.2M NaCl, which is
routinely used to isolate nucleoplasmic snRNPs, contained only
trace amounts of TAF15 (data not shown). To examine the
possibility that TAF15 and the U1-TAF15 snRNP associate with
chromatin, HeLa nuclei were extracted with increasing concen-
trations of NaCl in the presence or absence of RNase A (Fig 4A).
Without RNase, no significant amount of TAF15 was solubilized at
0.2M or lower salt concentrations. Increasing the salt concentra-
tion of the extraction buffer up to 1M supported the solubilization
of only about 50% of nuclear TAF15. Inclusion of RNase A
significantly facilitated the solubilization of TAF15 at each step,
indicating that TAF15 tightly interacts with chromatin in an
RNA-dependent manner.
To analyse further the subcellular distribution of TAF15
and, more importantly, the U1-TAF15 snRNP, HeLa cells were
fractionated into cytoplasmic, nucleoplasmic and chromatin
fractions (Fig 4B; supplementary information online). Nuclear
fractionation was confirmed by the detection of histone H3 in the
chromatin extract. TAF15 was not detectable in the cytoplasm, but
it was present in the nucleoplasmic fraction eluted with 350mM
salt and in the chromatin extract, where proteins were further
solubilized by micrococcal nuclease digestion. To test whether
the chromatin-associated fraction of TAF15 binds to U1 snRNA,
comparable amounts of TAF15 (after normalization of TAF15
amounts) were immunoprecipitated from the nucleoplasmic and
chromatin extracts (Fig 4C). The recovery of U1 snRNA was
monitored by RNase mapping and RT–qPCR (Fig 4D). TAF15
immunoprecipitated from the chromatin extract bound about four
times more U1 snRNA than did TAF15 derived from the
nucleoplasmic extract, indicating that the U1-TAF15 snRNP is
highly enriched in the chromatin of HeLa nuclei and that only a
fraction of the nuclear soluble form of TAF15 binds to U1 snRNA.
To characterize further the nuclear-soluble and the chromatin-
associated U1-TAF15 snRNPs, the nucleoplasmic and chromatin
extracts were size-fractionated by chromatography, and fractions
were analysed by Western blotting with antibodies specific for
TAF15, U1-70K, TBP and TAF5 (Fig 4E; supplementary Fig 4A
online). In both extracts, we detected high molecular weight
complexes in fractions 14–16, which contained TAF5, TBP and
TAF15. When distribution of the U1 snRNA was determined by
RT–qPCR and compared with that of U1-70K, it became apparent
that the U1-Sm snRNP eluted mainly in fractions 24–26 of both
nucleoplasmic and chromatin extracts. In contrast to U1-70K,
TAF15 eluted mainly in fractions 30–34 in both extracts, further
showing that U1-70K and TAF15 are present in different
complexes. When fractions 30–34, obtained by fractionation of
nucleoplasmic or chromatin extracts, were pooled and TAF15
was immunoprecipitated, the U1 snRNA was present in both
immunoprecipitations, showing that both the nucleoplasmic- and
chromatin-soluble forms of TAF15 associate with U1 snRNA
(Fig 4F; supplementary Figs 3B and 4C online).
As TAF15 was originally identified as a TFIID-associated
protein (Bertolotti et al, 1996), we investigated its interaction
with two components of TFIID, TBP and TAF5, in the size-
fractionated nucleoplasmic- and chromatin-soluble extracts
(supplementary Figs 3A and 4B online). In both cases, we found
that TAF15 eluted in the low molecular weight fractions (30–34),
which contain the U1-TAF15 snRNP, did not associate with TBP
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Fig 3 |Biogenesis of U1-TAF15 snRNP requires the U1 Sm motif.
(A) Accumulation of mutant U1 RNAs (U1sm1 to U1sm5) in transfected
(T) and non-transfected (N) HeLa cells was analysed by RNase mapping.
Structure of the phU1 expression construct is shown. Mappings with
Escherichia coli tRNA (C) and HeLa total RNA (H). (B) Distribution of
transiently expressed U1sm3 and U2sm RNAs in the cytoplasmic (Cy)
and nuclear (N) fractions of transfected HeLa cells (T) was determined
by RNase mapping. (C) Association of U1sm3 RNA (IN) with TAF15
and Sm proteins was assayed by immunoprecipitation with TAF15
and Sm antibodies followed by RNase mapping. –Ab, control-
immunoprecipitation; M, size marker; snRNP, small nuclear
ribonucleoprotein particle; TAF15, TBP-associated factor 15; tRNA,
transfer RNA.
Human U1 snRNA forms a new snRNP with TAF15
L. Jobert et al
&2009EUROPEAN MOLECULAR BIOLOGY ORGANIZATION EMBO reports VOL 10 | NO 5 | 2009
scientificreport
497and TAF5. By contrast, immunoprecipitation of TAF15 from the
large molecular size fractions (14–18) co-precipitated both TAF5
and TBP, but failed to pull down U1 snRNA (supplementary
Fig 4C online), indicating that TAF15 interacts with TFIID in a
U1-independent manner.
Stress-induced perinucleolar accumulation of U1-TAF15
As both TAF15 and U1 snRNAs have been implicated in Pol II
transcription, we investigated the interaction of U1 and TAF15 in
transcriptionally arrested HeLa cells (supplementary Fig 5 online).
Surprisingly, as compared with TAF15 immunoprecipitated from a
control extract, TAF15 immunoprecipitated from the extract of
a-amanitin-treated cells showed about 2.5-fold increase in U1
association, indicating that inhibition of Pol II transcription
increases the association of TAF15 with U1 snRNA.
Next, we determined the subnuclear localization of the
U1-TAF15 snRNP in a-amanitin-treated and control HeLa cells with
indirect immunofluorescence and fluorescent in situ hybridization
(Fig 5). In control cells, both TAF15 and U1 snRNAs localized
predominantly to the nucleoplasm, except that U1 showed
enrichments in the Cajal bodies and nucleoplasmic speckles
(Fig 5A). In cells treated with a-amanitin for 3h, both TAF15
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Fig 4 |The U1-TAF15 snRNP associates with chromatin. (A) HeLa nuclei were extracted with increasing concentrations of NaCl with or without RNase A.
After centrifugation the distribution of TAF15 in the soluble and insoluble fractions was determined by Western blot analysis and densitometric
scanning. (B) HeLa cell cytoplasmic- (Cy), nucleoplasmic- (Nu) and chromatin (Ch)-soluble fractions were prepared and analysed by Western blot.
(C) Nucleoplasmic and chromatin fractions were immunoprecipated with TAF15 or control antibodies. Co-precipitation of U1 snRNA was measured
by RNase mapping. (D) Measurement of the association of TAF15 with U1 by RT–qPCR. (E) HeLa chromatin-soluble fraction was fractionated by gel
filtration. The input (IN Ch) and even fractions were analysed by Western blot. The distribution of U1 snRNA was analysed by RT–qPCR. Molecular
mass markers are indicated. (F) Fractions 30–34 from (E) were pooled and subjected to immunoprecipitations with TAF15 or control antibodies.
Co-precipitation of U1 snRNA was measured by RNase mapping. IP, immunoprecipitation; RT–qPCR, reverse transcription–quantitative PCR; snRNP,
small nuclear ribonucleoprotein particle; TAF15, TBP-associated factor 15; TBP, TATA-binding protein.
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498and U1 were concentrated on the periphery of round-shaped
nucleoplasmic domains (Fig 5B). On transient expression of
a green fluorescent protein (GFP)-tagged nucleolar protein,
fibrillarin, it became apparent that U1 and TAF15 accumulated
in perinucleolar cap structures formed on the surface of nucleoli
entering transcription inhibition-induced segregation (Fig 5C and
D). After completion of nucleolar segregation (5–6h after a-
amanitin administration), the U1-70K snRNP protein is also
known to accumulate in the nucleolar caps (Carmo-Fonseca
et al, 1992; our unpublished data). In contrast to U1 snRNA,
neither U1-70K nor Sm snRNP proteins showed perinucleolar
accumulation 3h after a-amanitin administration, excluding the
possibility that U1 accumulated in the perinucleolar caps in the
form of U1-Sm snRNP (Fig 5E–H). Similarly, the U2-Sm snRNA
also failed to concentrate in the nucleolar caps of transcriptionally
arrested cells (Fig 5I and J), indicating that the U1-TAF15 snRNP
specifically translocates into perinucleolar caps already at an early
stage of nucleolar segregation.
The findings that both cellular accumulation and subnuclear
distribution of the U1-TAF15 snRNPs are sensitive to the
transcriptional activity of the cell might indicate that the
U1-TAF15 snRNPs have a Pol II transcription-dependent function.
By sequestering U1 snRNA into the U1-TAF15 snRNPs, TAF15
might negatively regulate either the spliceosomal function of
the U1-Sm snRNP or the transcription initiation function of the
U1–TFIIH complex (Kwek et al, 2002). Recently, non-coding
RNAs localized to the regulatory regions of transcription units
were shown to recruit and modulate the activity of the TET
proteins in response to specific signals (Wang et al, 2008). Thus,
our study might indicate that the inhibition of Pol II transcription
increases the amount of chromatin-associated U1-TAF15 snRNP
through the recruitment of more TAF15 from the nuclear-‘soluble’
pool to chromatin. These results might also suggest that the
U1-TAF15 snRNP acts following specific signals such as inhibition
of Pol II transcription.
In conclusion, we have shown that human U1 snRNA forms at
least two structurally and, most likely, functionally distinct snRNP
particles. Our findings strongly support the idea that U1 snRNA
has many nuclear functions and highlight the intriguing possibility
that non-coding RNAs with well-established functions might
participate in several cellular processes.
METHODS
Immunoprecipitation and Western blot analysis. Proteins from
500mg of nuclear extract were immunoprecipitated with 50mlo f
protein G-Sepharose (Amersham Pharmacia Biotech, Uppsala,
Sweden) and approximately 5–10mg of the various antibodies as
described previously (Bertolotti et al, 1996), except that immuno-
precipitation buffers containing NaCl instead of KCl were used.
Western blot and chemiluminescence detection were performed
according to the manufacturer’s instructions (Amersham Pharmacia).
Extraction of RNA and analysis of TAF15-bound nucleic
acids. RNAs from TAF15 immunoprecipitations were isolated
by the guanidinium thiocyanate/phenol–chloroform extraction
method. RNA 30 end labelling with [50-32P]pCp and T4 RNA ligase
(New England BioLabs, Hitchin, UK) and RNase A/T1 protection
assay were performed. To generate sequence-specific antisense
RNA probes, recombinant pBluescribe plasmids carrying full-
length cDNAs of the human U1, U2 or U4 snRNAs were
U1 snRNA TAF15 Merge DAPI
U1 snRNA Fibrillarin Merge DAPI
U1 snRNA U1-70K Merge DAPI
U1 snRNA Sm Merge DAPI
U1 snRNA U2 snRNA Merge DAPI
Control
α-amanitin
Control
Control
α-amanitin
α-amanitin
Control
α-amanitin
Control
α-amanitin
A
B
C
D
E
F
G
H
I
J
Fig 5 |Transcription-dependent subnuclear localization of U1-TAF15
snRNP. HeLa cells treated either with 20mg/ml a-amanitin for 3h
or with non-treated (control) were probed with fluorescent
oligonucleotides complementary to the human U1 and U2 snRNA,
and with antibodies specific for TAF15, U1-70K and Sm proteins.
Nucleoli were stained by transient expression of fibrillarin-GFP and
DNA was visualized by DAPI staining. DAPI, 4,6-diamidino-2-
phenylindole; GFP, green fluorescent protein; snRNA, small nuclear
RNA; snRNP, small nuclear ribonucleoprotein particle; TAF15,
TBP-associated factor 15.
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499linearized and used as templates for in vitro transcription with
the T7 RNA polymerase (Promega, France) in the presence of
[a-32P]CTP (30Ci/mmol).
Immunofluorescence and in situ hybridization. Fixation, permea-
bilization, immunostaining, in situ hybridization of HeLa cells,
synthesis and chemical conjugation of amino-modified oligo-
nucleotides with Fluoro-Link Cy3 and Cy5 monofunctional dyes
were performed as described at http://singerlab.aecom.yu.edu.
Further experimental procedures are provided in the supple-
mentary information online.
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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